Novocure reports Q1 EPS (62c), consensus (51c)

Reports 1Q revenue $174.055M, consensus $167.77M. “This was a very strong start to the year for Novocure (NVCR) and we are pleased with the progress made across our commercial and clinical programs,” said Frank Leonard, CEO, Novocure. “We reached several key milestones in the first quarter and are eager to maintain this momentum as we approach numerous exciting catalysts later this year. Our focus remains on bringing Tumor Treating Fields therapy to patients diagnosed with some of the most aggressive forms of cancer, further exploring the use of our therapy to benefit patients in need, and achieving sustainable growth and profitability.”